These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 24732667)

  • 1. Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation.
    Martín R; Chain F; Miquel S; Natividad JM; Sokol H; Verdu EF; Langella P; Bermúdez-Humarán LG
    Hum Vaccin Immunother; 2014; 10(6):1611-21. PubMed ID: 24732667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventative delivery of IL-35 by Lactococcus lactis ameliorates DSS-induced colitis in mice.
    Wang J; Tian M; Li W; Hao F
    Appl Microbiol Biotechnol; 2019 Oct; 103(19):7931-7941. PubMed ID: 31456001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.
    Steidler L; Hans W; Schotte L; Neirynck S; Obermeier F; Falk W; Fiers W; Remaut E
    Science; 2000 Aug; 289(5483):1352-5. PubMed ID: 10958782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein.
    Foligne B; Dessein R; Marceau M; Poiret S; Chamaillard M; Pot B; Simonet M; Daniel C
    Gastroenterology; 2007 Sep; 133(3):862-74. PubMed ID: 17678918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lactococcus lactis carrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis.
    Zurita-Turk M; Del Carmen S; Santos AC; Pereira VB; Cara DC; Leclercq SY; de LeBlanc Ad; Azevedo V; Chatel JM; LeBlanc JG; Miyoshi A
    BMC Biotechnol; 2014 Aug; 14():73. PubMed ID: 25106058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci.
    Bermúdez-Humarán LG; Motta JP; Aubry C; Kharrat P; Rous-Martin L; Sallenave JM; Deraison C; Vergnolle N; Langella P
    Microb Cell Fact; 2015 Feb; 14():26. PubMed ID: 25889561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral delivery of Lactococcus lactis that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice.
    Shigemori S; Watanabe T; Kudoh K; Ihara M; Nigar S; Yamamoto Y; Suda Y; Sato T; Kitazawa H; Shimosato T
    Microb Cell Fact; 2015 Nov; 14():189. PubMed ID: 26608030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model.
    del Carmen S; Martín Rosique R; Saraiva T; Zurita-Turk M; Miyoshi A; Azevedo V; de Moreno de LeBlanc A; Langella P; Bermúdez-Humarán LG; LeBlanc JG
    J Clin Gastroenterol; 2014; 48 Suppl 1():S12-7. PubMed ID: 25291117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces.
    Benbouziane B; Ribelles P; Aubry C; Martin R; Kharrat P; Riazi A; Langella P; Bermúdez-Humarán LG
    J Biotechnol; 2013 Oct; 168(2):120-9. PubMed ID: 23664884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa.
    Simčič S; Berlec A; Stopinšek S; Štrukelj B; Orel R
    World J Microbiol Biotechnol; 2019 Feb; 35(3):45. PubMed ID: 30810891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice.
    Vandenbroucke K; Hans W; Van Huysse J; Neirynck S; Demetter P; Remaut E; Rottiers P; Steidler L
    Gastroenterology; 2004 Aug; 127(2):502-13. PubMed ID: 15300583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin.
    Huibregtse IL; Snoeck V; de Creus A; Braat H; De Jong EC; Van Deventer SJ; Rottiers P
    Gastroenterology; 2007 Aug; 133(2):517-28. PubMed ID: 17681173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral delivery of pancreatitis-associated protein by Lactococcus lactis displays protective effects in dinitro-benzenesulfonic-acid-induced colitis model and is able to modulate the composition of the microbiota.
    Breyner NM; Vilas Boas PB; Fernandes G; de Carvalho RD; Rochat T; Michel ML; Chain F; Sokol H; de Azevedo M; Myioshi A; Azevedo VA; Langella P; Bermúdez-Humarán LG; Chatel JM
    Environ Microbiol; 2019 Nov; 21(11):4020-4031. PubMed ID: 31325218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice.
    Hanson ML; Hixon JA; Li W; Felber BK; Anver MR; Stewart CA; Janelsins BM; Datta SK; Shen W; McLean MH; Durum SK
    Gastroenterology; 2014 Jan; 146(1):210-221.e13. PubMed ID: 24120477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactococcus lactis engineered to deliver hCAP18 cDNA alleviates DNBS-induced colitis in C57BL/6 mice by promoting IL17A and IL10 cytokine expression.
    Noguès EB; Kropp C; Bétemps L; de Sousa C; Chain F; Auger S; Azevedo V; Langella P; Chatel JM
    Sci Rep; 2022 Sep; 12(1):15641. PubMed ID: 36123355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral delivery of a Lactococcus lactis strain secreting bovine lactoferricin-lactoferrampin alleviates the development of acute colitis in mice.
    Song L; Xie W; Liu Z; Guo D; Zhao D; Qiao X; Wang L; Zhou H; Cui W; Jiang Y; Li Y; Xu Y; Tang L
    Appl Microbiol Biotechnol; 2019 Aug; 103(15):6169-6186. PubMed ID: 31165225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice.
    Waeytens A; Ferdinande L; Neirynck S; Rottiers P; De Vos M; Steidler L; Cuvelier CA
    Inflamm Bowel Dis; 2008 Apr; 14(4):471-9. PubMed ID: 18092343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal delivery of Lactococcus lactis carrying an anti-TNF scFv expression vector ameliorates experimental colitis in mice.
    Chiabai MJ; Almeida JF; de Azevedo MGD; Fernandes SS; Pereira VB; de Castro RJA; Jerônimo MS; Sousa IG; de Souza Vianna LM; Miyoshi A; Bocca AL; Maranhão AQ; Brigido MM
    BMC Biotechnol; 2019 Jun; 19(1):38. PubMed ID: 31238939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms.
    Meynier M; Baudu E; Rolhion N; Defaye M; Straube M; Daugey V; Modoux M; Wawrzyniak I; Delbac F; Villéger R; Méleine M; Borras Nogues E; Godfraind C; Barnich N; Ardid D; Poirier P; Sokol H; Chatel JM; Langella P; Livrelli V; Bonnet M; Carvalho FA
    Gut Microbes; 2022; 14(1):2022997. PubMed ID: 35090380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive Lactococcus lactis producing mycobacterial Hsp65 ameliorates intestinal inflammation in acute TNBS-induced colitis in mice by increasing the levels of the cytokine IL-10 and secretory IgA.
    da Cunha VP; Preisser TM; Santana MP; Machado DCC; Pereira VB; Miyoshi A
    J Appl Microbiol; 2020 Nov; 129(5):1389-1401. PubMed ID: 32473073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.